Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scinai Immunotherapeutics Ltd SCNI

Healthcare Biotechnology
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various... see more

Recent & Breaking News (NDAQ:SCNI)

25 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  March 7, 2017

15 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  January 17, 2017

18 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  January 17, 2017

Back to the Future: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't yet Exist

PR Newswire January 12, 2017

BiondVax Receives $US 2.8 Million Investment From Angels High Tech Investments Ltd.

PR Newswire January 2, 2017

BiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well Tolerated

PR Newswire November 29, 2016

BiondVax Announces Third Quarter 2016 Financial Results and Update

PR Newswire November 28, 2016

Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVax’s Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains

PR Newswire November 22, 2016

BiondVax Phase 2b European Trial: Last Patient Out

PR Newswire September 21, 2016

BiondVax Announces Second Quarter 2016 Financial Results and Update

PR Newswire August 18, 2016

BiondVax CEO to Present Universal Flu Vaccine Technology at BIO International Convention

PR Newswire June 2, 2016

BiondVax Announces First Quarter 2016 Financial Results and Update

PR Newswire May 31, 2016

BiondVax to Present Tomorrow at Joseph Gunner Pioneers 2016 Conference

PR Newswire May 4, 2016

BiondVax's Universal Flu Vaccine Phase 2b Clinical Trial Recruitment Complete

PR Newswire March 28, 2016

BiondVax CEO to Present at Roth Conference on Wednesday, March 16

PR Newswire March 7, 2016

BiondVax Receives Additional Grant Approval

PR Newswire February 18, 2016

Biondvax's Universal Flu Vaccine Receives Additional US Patent

PR Newswire January 27, 2016

BiondVax Receives Approval for a Patent for its Universal Flu Vaccine in Israel

PR Newswire December 21, 2015

BiondVax to Bring Long-Awaited Universal Flu Vaccine to the Market

PR Newswire December 3, 2015

BiondVax Announces Upcoming Investor Events: Presenting at the LD Micro Conference in Los Angeles Following Investor Non-deal Roadshow

PR Newswire November 5, 2015